Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Medmira (TSV:MIR)

0.0950 +0.0050 (+5.56%)
Streaming Delayed Price Updated: 9:32 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 78,605
Open 0.0950
Bid (Size) 0.0900 (70)
Ask (Size) 0.0950 (70)
Prev. Close 0.0900
Today's Range 0.0950 - 0.0950
52wk Range 0.0700 - 0.1400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
Via ACCESS Newswire
MedMira Reports Second Quarter Results FY2025
Via ACCESS Newswire

Performance

YTD
-13.6%
-13.6%
1 Month
-13.6%
-13.6%
3 Month
-26.9%
-26.9%
6 Month
+18.8%
+18.8%
1 Year
+18.8%
+18.8%

More News

Read More
MedMira Announces Partnership with MediGroup Physician Services in the United States
Via ACCESS Newswire
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
Via ACCESS Newswire
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
Via ACCESS Newswire
MedMira Reports First Quarter Results FY2025
Via ACCESSWIRE
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
Via ACCESSWIRE
MedMira Announces the appointment of Vice President of Commercial Operations
Via ACCESSWIRE
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
Via ACCESSWIRE
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
Via ACCESSWIRE
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
Via ACCESSWIRE
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
Via ACCESSWIRE
MedMira Reports Third Quarter Results FY2024
Via ACCESSWIRE
MedMira Announces the Hire of Vice President of Business Development
Via ACCESSWIRE
MedMira Reports Second Quarter Results FY2024
Via ACCESSWIRE
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
Via ACCESSWIRE
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
Via ACCESSWIRE
Corporate Update on Clinical Evaluation of MedMira’s Products
Via ACCESSWIRE
MedMira Reports First Quarter Results FY2024
Via ACCESSWIRE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
Via ACCESSWIRE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
Via ACCESSWIRE
Update on MedMira’s Regulatory Path in Canada and the USA
Via ACCESSWIRE
Progress Update on Securities
Via ACCESSWIRE
MedMira Reports Third Quarter Results FY2023
Via ACCESSWIRE
MedMira Reports Second Quarter Results FY2023
Via ACCESSWIRE

Frequently Asked Questions

Is Medmira publicly traded?
Yes, Medmira is publicly traded.
What exchange does Medmira trade on?
Medmira trades on the Toronto Venture Stock Exchange
What is the ticker symbol for Medmira?
The ticker symbol for Medmira is MIR on the Toronto Venture Stock Exchange
What is the current price of Medmira?
The current price of Medmira is 0.0950
When was Medmira last traded?
The last trade of Medmira was at 04/17/25 09:32 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.